IN2012DN02604A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02604A
IN2012DN02604A IN2604DEN2012A IN2012DN02604A IN 2012DN02604 A IN2012DN02604 A IN 2012DN02604A IN 2604DEN2012 A IN2604DEN2012 A IN 2604DEN2012A IN 2012DN02604 A IN2012DN02604 A IN 2012DN02604A
Authority
IN
India
Prior art keywords
antibodies
antigen
binding fragments
gcc
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
S Nam Samuel
A Greenfield Edward
Babcook John
O'keefe Theresa
Qin Shixin
Original Assignee
Millennium Pharm Inc
Amgen British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Amgen British Columbia filed Critical Millennium Pharm Inc
Publication of IN2012DN02604A publication Critical patent/IN2012DN02604A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IN2604DEN2012 2009-10-23 2010-10-22 IN2012DN02604A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25447409P 2009-10-23 2009-10-23
PCT/US2010/053686 WO2011050242A1 (fr) 2009-10-23 2010-10-22 Molécules d'anticorps anti-gcc, compositions et procédés apparentés

Publications (1)

Publication Number Publication Date
IN2012DN02604A true IN2012DN02604A (fr) 2015-09-04

Family

ID=43900696

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2604DEN2012 IN2012DN02604A (fr) 2009-10-23 2010-10-22

Country Status (32)

Country Link
US (3) US8785600B2 (fr)
EP (2) EP3520816B1 (fr)
JP (2) JP5925684B2 (fr)
KR (2) KR101834890B1 (fr)
CN (3) CN102573908B (fr)
AR (1) AR078751A1 (fr)
AU (1) AU2010310545C1 (fr)
BR (1) BR112012007523A2 (fr)
CA (2) CA3031851C (fr)
CL (1) CL2012000806A1 (fr)
CR (1) CR20120124A (fr)
DO (1) DOP2012000066A (fr)
EA (2) EA030827B1 (fr)
EC (1) ECSP12011761A (fr)
ES (1) ES2788457T3 (fr)
GE (2) GEP20196956B (fr)
IL (3) IL218763A (fr)
IN (1) IN2012DN02604A (fr)
MA (1) MA33601B1 (fr)
MX (3) MX2012003198A (fr)
MY (1) MY173390A (fr)
NZ (2) NZ598791A (fr)
PE (1) PE20121542A1 (fr)
PH (1) PH12019500438A1 (fr)
PL (1) PL2490720T3 (fr)
SA (1) SA110310795B1 (fr)
SG (3) SG179567A1 (fr)
TN (1) TN2012000122A1 (fr)
TW (2) TWI583394B (fr)
UA (1) UA108991C2 (fr)
WO (1) WO2011050242A1 (fr)
ZA (1) ZA201201944B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
WO2007039256A2 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
EP2033971A1 (fr) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Domaines de protéines recombinantes des protéines morphogénétiques osseuses (BMP) de la famille des Repulsive Guidance Molecule (RGM) et leurs fragments fonctionnels ainsi que leur utilisation
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101834890B1 (ko) 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
KR101844479B1 (ko) 2011-11-17 2018-04-03 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
LT2841575T (lt) * 2012-04-27 2019-10-10 Millennium Pharmaceuticals, Inc. Antikūno molekulės, nukreiptos prieš gcc, ir jų panaudojimas nustatant jautrumą į gcc nukreiptai terapijai
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TW201444577A (zh) * 2013-02-28 2014-12-01 Millennium Pharm Inc 投予抗－ｇｃｃ抗體－藥物共軛物及ｄｎａ破壞劑來治療癌症
US10570151B2 (en) * 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
JP2015209384A (ja) * 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
EA201891723A1 (ru) * 2016-02-05 2018-12-28 Милленниум Фармасьютикалз, Инк. Gcc-направленные конъюгаты антитело-лекарство
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
KR101928079B1 (ko) 2016-12-12 2018-12-11 한화케미칼 주식회사 디시클로펜타디엔계 수지의 제조 방법 및 디시클로펜타디엔계 수지
CN116672463A (zh) * 2017-02-17 2023-09-01 浙江特瑞思药业股份有限公司 靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
CN108452319A (zh) * 2017-02-20 2018-08-28 浙江特瑞思药业股份有限公司 靶向cd20的抗体偶联药物制剂
JP2021520229A (ja) * 2018-03-16 2021-08-19 トーマス ジェファーソン ユニバーシティ 抗ｇｕｃｙ２ｃキメラ抗原受容体の組成物および方法
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
JP2022532192A (ja) 2019-05-10 2022-07-13 武田薬品工業株式会社 抗体薬物複合体
EP4045532A4 (fr) * 2019-10-14 2024-02-28 Scripps Research Inst Anticorps humains largement neutralisants contre la région externe proximale-membranaire d'env du vih pour la conception et l'intervention vaccinales
WO2022098372A1 (fr) * 2020-11-07 2022-05-12 Thomas Jefferson University Vaccins anti-gucy2c et vaccination
WO2021205325A1 (fr) * 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
US20210371492A1 (en) * 2020-06-02 2021-12-02 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC Antibody and CAR thereof for Treating Digestive System Cancer
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
AU2022219373A1 (en) 2021-02-15 2023-08-24 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
WO2022216079A1 (fr) * 2021-04-07 2022-10-13 주식회사 엘지화학 Polypeptide de liaison de gucy2c et ses utilisations
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
WO2024067762A1 (fr) * 2022-09-28 2024-04-04 Nanjing Legend Biotech Co., Ltd. Anticorps et récepteurs antigéniques chimériques ciblant gcc et leurs procédés d'utilisation
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35500A (en) 1862-06-10 Improvement in dampers
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1319120C (fr) 1985-04-01 1993-06-15 John Henry Kenten Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0552108B1 (fr) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Essai fluoro-immunologique impliquant un transfert d'énergie par phase-modulation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
EP0627932B1 (fr) 1992-11-04 2002-05-08 City Of Hope Structure d'anticorps
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0804070B1 (fr) 1993-03-09 2000-05-24 Genzyme Corporation PROCEDE D'ISOLEMENT DE PROTEINES du LAIT
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US6060037A (en) 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997008320A1 (fr) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
WO1997023243A1 (fr) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Segments de liaison hydrazone ramifies
EP0951475B1 (fr) 1996-05-03 2003-07-16 Thomas Jefferson University Vaccin contre le cancer recto-colique metastatique
WO1997042506A1 (fr) 1996-05-03 1997-11-13 Thomas Jefferson University Procedes et trousses de diagnostic et compositions permettant de diagnostiquer des tumeurs colorectales et leurs metastases
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6340463B1 (en) 1996-08-14 2002-01-22 Vanderbilt University Identification of antigenic peptide sequences
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
GB9700154D0 (en) 1997-01-07 1997-02-26 Primapharma Ltd Peptides
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
MXPA01005562A (es) 1998-11-03 2003-08-01 Centocor Inc Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad.
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
US6132922A (en) 1999-01-06 2000-10-17 Advanced Color Technology, Inc. Liquid developer for electrophotographic printing apparatus
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2000075662A1 (fr) * 1999-06-09 2000-12-14 Ljl Biosystems, Inc. Essais uur la signalisation cellulaire
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
FR2805994A1 (fr) 2000-03-10 2001-09-14 Agronomique Inst Nat Rech Methode de detection de la guanylyl cyclase-c et son utilisation pour le diagnostic des tumeurs colorectales metastatiques
EP1268854A4 (fr) * 2000-03-27 2003-05-02 Univ Jefferson Detection de marqueur a specificite levee
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA03006651A (es) 2001-01-26 2004-11-12 Inhibitex Inc Anticuerpos monoclonales para la proteina clfa y metodos para el uso en el tratamiento o prevencion de infecciones.
EA006651B1 (ru) 2001-03-29 2006-02-24 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазного рецептора для лечения тканевого воспаления и канцерогенеза
AU2002311556A1 (en) * 2001-03-30 2002-10-15 University Of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
EP1433793A4 (fr) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Procede pour creer une banque d'anticorps de chameaux
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
EP1443961B1 (fr) 2001-10-25 2009-05-06 Genentech, Inc. Compositions de glycoproteine
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2289174T3 (es) * 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
EP2357006B1 (fr) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (fr) 2003-02-10 2010-09-08 Univ Jefferson Utilisation de ligands gcc
EP1627062A1 (fr) * 2003-05-14 2006-02-22 Domantis Limited Procede de recuperation de polypeptides qui se deplient de facon reversible a partir d'un repertoire de polypeptides
AU2004259398A1 (en) * 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US7662936B2 (en) 2004-04-07 2010-02-16 Genentech, Inc. Mass spectrometry of antibody conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1781339B1 (fr) 2004-06-25 2013-12-25 Thomas Jefferson University Ligands de la Guanylyle cyclase C
EP3505191A1 (fr) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatines comportant une unité d'acide aminobenzoïque au niveau du n terminal
EP2284194A1 (fr) * 2004-12-21 2011-02-16 AstraZeneca AB Anticorps dirigés contre l'Angiopoiétine 2 et leurs utilisations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647282A1 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
BRPI0814355A2 (pt) 2007-08-10 2015-01-27 Centocor Ortho Biotech Inc Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos
PT2187964E (pt) * 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
EP2211904B1 (fr) 2007-10-19 2016-08-17 Seattle Genetics, Inc. Agents de liaison au cd19 et utilisations de ceux-ci
JP2011505795A (ja) 2007-11-27 2011-03-03 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド バリアントｎｆｋｂｉｂの癌関連エピトープに対する抗体およびその使用
EP2220492B1 (fr) 2007-11-30 2011-08-31 Genentech, Inc. Polymorphismes du vegf et thérapie anti-angiogenèse
CA2760050A1 (fr) 2008-05-13 2009-11-19 Thomas Jefferson University Rt-pct quantitative de la guanylyl cyclase c
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2370098A4 (fr) * 2008-12-03 2013-07-17 Morphosys Ag Anticorps contre les récepteurs de guanylyle cyclase
CA2744236C (fr) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Expression de la proteine mutante ros dans les cancers chez l'etre humain
EP2401394B1 (fr) 2009-02-25 2013-11-27 Diagnocure Inc. Procédé de détection de métastase d'un cancer du tractus gastro-intestinal
EP2407786A4 (fr) 2009-03-12 2013-01-02 Univ Kinki Procédé permettant de prédire l'efficacité thérapeutique de la chimiothérapie sur le cancer du poumon non à petites cellules
WO2010147684A1 (fr) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions et procédés d'activation de la guanylyl cyclase c
EP2491116A4 (fr) 2009-10-22 2013-12-11 Univ Jefferson Compositions anti-cancéreuses à base de cellules et leurs procédés de production et d'utilisation
KR101834890B1 (ko) 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
WO2011150454A1 (fr) 2010-06-01 2011-12-08 Monash University Anticorps dirigés contre le récepteur tyrosine kinase c-met
WO2012020123A2 (fr) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Utilisation de la neuropiline comme biomarqueur pour des traitements combinés à base de bevacizumab
US20150086481A1 (en) * 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
LT2841575T (lt) 2012-04-27 2019-10-10 Millennium Pharmaceuticals, Inc. Antikūno molekulės, nukreiptos prieš gcc, ir jų panaudojimas nustatant jautrumą į gcc nukreiptai terapijai
TW201444577A (zh) 2013-02-28 2014-12-01 Millennium Pharm Inc 投予抗－ｇｃｃ抗體－藥物共軛物及ｄｎａ破壞劑來治療癌症
EP3077407A4 (fr) 2013-12-03 2017-07-19 Millennium Pharmaceuticals, Inc. Composés et compositions pour l'imagerie de cellules exprimant gcc
EA201891723A1 (ru) 2016-02-05 2018-12-28 Милленниум Фармасьютикалз, Инк. Gcc-направленные конъюгаты антитело-лекарство
CN109219445B (zh) 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用

Also Published As

Publication number Publication date
CA3031851A1 (fr) 2011-04-28
EA201792376A3 (ru) 2018-08-31
PH12019500438A1 (en) 2020-07-20
EA030827B1 (ru) 2018-10-31
SA110310795B1 (ar) 2014-07-14
US8785600B2 (en) 2014-07-22
TWI483736B (zh) 2015-05-11
ECSP12011761A (es) 2012-05-30
CA2774032A1 (fr) 2011-04-28
MA33601B1 (fr) 2012-09-01
MY173390A (en) 2020-01-22
EP3520816A2 (fr) 2019-08-07
MX2019008956A (es) 2019-09-13
EP3520816B1 (fr) 2022-08-31
CN110054692A (zh) 2019-07-26
IL218763A0 (en) 2012-06-28
SG10201407757XA (en) 2015-01-29
GEP20196956B (en) 2019-03-25
CA3031851C (fr) 2020-07-07
EP3520816A3 (fr) 2019-10-09
AU2010310545A8 (en) 2012-10-11
UA108991C2 (uk) 2015-07-10
EP2490720A1 (fr) 2012-08-29
WO2011050242A1 (fr) 2011-04-28
AR078751A1 (es) 2011-11-30
CA2774032C (fr) 2019-03-26
JP5925684B2 (ja) 2016-05-25
EA201792376A2 (ru) 2018-03-30
AU2010310545A1 (en) 2012-05-17
JP2013507968A (ja) 2013-03-07
IL218763A (en) 2016-10-31
TW201132352A (en) 2011-10-01
US20110110936A1 (en) 2011-05-12
US20180355062A1 (en) 2018-12-13
KR20120128120A (ko) 2012-11-26
TW201524517A (zh) 2015-07-01
MX366890B (es) 2019-07-30
NZ623607A (en) 2016-07-29
CN104447996A (zh) 2015-03-25
ZA201201944B (en) 2013-05-29
EP2490720A4 (fr) 2013-06-05
KR20170123723A (ko) 2017-11-08
MX2012003198A (es) 2012-06-12
EP2490720B1 (fr) 2020-02-12
IL247842B (en) 2018-06-28
TN2012000122A1 (en) 2013-09-19
CN102573908B (zh) 2014-12-17
TWI583394B (zh) 2017-05-21
CR20120124A (es) 2012-07-04
IL260285A (en) 2018-07-31
KR101834890B1 (ko) 2018-04-20
CL2012000806A1 (es) 2012-08-03
ES2788457T3 (es) 2020-10-21
CN102573908A (zh) 2012-07-11
PE20121542A1 (es) 2012-12-06
SG179567A1 (en) 2012-05-30
IL260285B (en) 2019-08-29
AU2010310545B2 (en) 2014-11-06
US10941211B2 (en) 2021-03-09
EA201270365A1 (ru) 2012-09-28
PL2490720T3 (pl) 2020-08-24
NZ598791A (en) 2014-05-30
JP2016028603A (ja) 2016-03-03
BR112012007523A2 (pt) 2017-06-20
AU2010310545C1 (en) 2015-04-30
US20140322233A1 (en) 2014-10-30
SG10202011656XA (en) 2020-12-30
DOP2012000066A (es) 2013-04-15
GEP20166504B (en) 2016-06-27

Similar Documents

Publication Publication Date Title
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
WO2006104677A3 (fr) Anticorps se liant a ov064 et leurs methodes d'utilisation
EP3593812A3 (fr) Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
EP2582722A4 (fr) Anticorps contre gd2
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX355181B (es) Anticuerpos humanos contra el factor tisular.
WO2011143624A3 (fr) Anticorps monoclonaux anti-cd47 humanisés et chimères
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MY166776A (en) Humanised anti-ctla4 antibodies
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
WO2009120905A3 (fr) Protéines de récepteurs d'immunoglobuline et/ou de récepteurs toll associées à des troubles prolifératifs hématologiques myélogènes et utilisations correspondantes
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
WO2011031833A3 (fr) Anticorps anticancéreux pour humains
EP2279203A4 (fr) Épitopes de prion et leur procédé d utilisation
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof